Startseite>>Lipids>> Sterol Lipids>>7β,27-dihydroxy Cholesterol

7β,27-dihydroxy Cholesterol (Synonyms: 7β,27-DHC)

Katalog-Nr.GC46740

An oxysterol and agonist of RORγ and RORγt

Products are for research use only. Not for human use. We do not sell to patients.

7β,27-dihydroxy Cholesterol Chemische Struktur

Cas No.: 240129-43-5

Größe Preis Lagerbestand Menge
500 μg
170,00 $
Auf Lager
1 mg
321,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

7β,27-dihydroxy Cholesterol is an oxysterol and agonist of retinoic acid receptor-related orphan receptor γ (RORγ) and RORγt. [1]  It activates RORγ- or RORγt-dependent signaling with EC50 values of 691 and 1,045 nM, respectively, in reporter assays using HEK293T cells expressing the recombinant human receptors. 7β,27-dihydroxy Cholesterol is selective for RORγ and RORγt over a panel of eight additional nuclear receptors at 30 µM. It increases IL-17A production in Th17-polarized isolated human naÏve CD4+ T cells when used at a concentration of 300 nM. 7β,27-dihydroxy Cholesterol (60 mg/kg) increases IL-17A production in isolated mouse γδ T cells stimulated with 12-myristate 13-acetate and ionomycin .

Reference:
[1].Soroosh, P., Wu, J., Xue, X., et al.Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiationProc. Natl. Acad. Sci. USA111(33)12163-12168(2014)

Bewertungen

Review for 7β,27-dihydroxy Cholesterol

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 7β,27-dihydroxy Cholesterol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.